Brigitt E. Abbuehl

548 total citations
18 papers, 442 citations indexed

About

Brigitt E. Abbuehl is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Brigitt E. Abbuehl has authored 18 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 3 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Brigitt E. Abbuehl's work include Hemophilia Treatment and Research (18 papers), Platelet Disorders and Treatments (11 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Brigitt E. Abbuehl is often cited by papers focused on Hemophilia Treatment and Research (18 papers), Platelet Disorders and Treatments (11 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Brigitt E. Abbuehl collaborates with scholars based in United States, Austria and Poland. Brigitt E. Abbuehl's co-authors include Oleksandra Stasyshyn, Werner Engl, Bruce M. Ewenstein, Barbara A. Konkle, Midori Shima, Tim Mant, Pratima Chowdary, David Bevan, Lisa Patrone and Jerzy Windyga and has published in prestigious journals such as Blood, Thrombosis and Haemostasis and Haemophilia.

In The Last Decade

Brigitt E. Abbuehl

18 papers receiving 431 citations

Peers

Brigitt E. Abbuehl
Ségolène Claeyssens‐Donadel France
F. Abdul Karim Denmark
Glaivy Batsuli United States
Atanas Radinoff Bulgaria
Alice S. van Velzen Netherlands
C. Escuriola‐Ettingshausen Germany
María Abáigar Spain
Rabia Shahswar Germany
Monika Kutyna Australia
Ian F. Thomas United Kingdom
Ségolène Claeyssens‐Donadel France
Brigitt E. Abbuehl
Citations per year, relative to Brigitt E. Abbuehl Brigitt E. Abbuehl (= 1×) peers Ségolène Claeyssens‐Donadel

Countries citing papers authored by Brigitt E. Abbuehl

Since Specialization
Citations

This map shows the geographic impact of Brigitt E. Abbuehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitt E. Abbuehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitt E. Abbuehl more than expected).

Fields of papers citing papers by Brigitt E. Abbuehl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitt E. Abbuehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitt E. Abbuehl. The network helps show where Brigitt E. Abbuehl may publish in the future.

Co-authorship network of co-authors of Brigitt E. Abbuehl

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitt E. Abbuehl. A scholar is included among the top collaborators of Brigitt E. Abbuehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitt E. Abbuehl. Brigitt E. Abbuehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nogami, Keiji, Midori Shima, Katsuyuki Fukutake, et al.. (2017). Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations. International Journal of Hematology. 106(5). 704–710. 7 indexed citations
2.
Mullins, Eric S., Oleksandra Stasyshyn, David Osman, et al.. (2016). Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 23(2). 238–246. 62 indexed citations
3.
Brand, B., Ralph A. Gruppo, Tung Wynn, et al.. (2016). Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patients. Haemophilia. 22(4). e251–8. 23 indexed citations
4.
Windyga, Jerzy, et al.. (2016). Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial. Blood. 128(22). 2585–2585. 1 indexed citations
5.
Horling, Frank, Peter Allacher, Herwig Koppensteiner, et al.. (2016). Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α. Blood. 128(22). 2594–2594. 1 indexed citations
6.
Manco‐Johnson, Marilyn J., D. Alice, Robert Klamroth, et al.. (2015). Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855). Blood. 126(23). 2300–2300. 2 indexed citations
7.
Konkle, Barbara A., Oleksandra Stasyshyn, Pratima Chowdary, et al.. (2015). Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 126(9). 1078–1085. 207 indexed citations
8.
9.
Windyga, Jerzy, Brigitt E. Abbuehl, & Andrea E. Hafeman. (2014). BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B. Expert Review of Hematology. 7(3). 333–342. 7 indexed citations
10.
11.
Stasyshyn, Oleksandra, T. A. Andreeva, L. Rusen, et al.. (2014). Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial. Haemophilia. 21(2). 196–203. 7 indexed citations
12.
Stasyshyn, Oleksandra, L. Rusen, M. Şerban, et al.. (2014). Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326). Haemophilia. 20(5). 674–681. 6 indexed citations
13.
14.
15.
16.
Auerswald, G., Alexis A. Thompson, Michael Recht, et al.. (2012). Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thrombosis and Haemostasis. 107(6). 1072–1082. 35 indexed citations
17.
18.
Spotts, Gerald, Brigitt E. Abbuehl, Norma Guzmán‐Becerra, et al.. (2010). Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).. Blood. 116(21). 3670–3670. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ségolène Claeyssens‐Donadel Breakdown of academic impact, for papers by F. Abdul Karim Breakdown of academic impact, for papers by Glaivy Batsuli Breakdown of academic impact, for papers by Atanas Radinoff Breakdown of academic impact, for papers by Alice S. van Velzen Breakdown of academic impact, for papers by C. Escuriola‐Ettingshausen Breakdown of academic impact, for papers by María Abáigar Breakdown of academic impact, for papers by Rabia Shahswar Breakdown of academic impact, for papers by Monika Kutyna Breakdown of academic impact, for papers by Ian F. Thomas
Rankless by CCL
2026